

The Alere Cholestech LDX® System



Complete Lipid Profile

as recommended by the National Cholesterol Education Program guidelines^{1,2}

Give your patients an advantage
in CVD prevention and management.

Over one-third of Americans with high LDL cholesterol have not been screened.³ The latest clinical trials show a benefit of intensifying therapy for primary and secondary prevention of cardiovascular disease (CVD). Yet national surveys consistently show that many patients – especially those most at risk – are not at their therapeutic lipid goals.³⁻⁵

*The #1 CLIA-Waived
Lipid Testing System*



Alere

Call 1.877.441.7440 or visit alere.com today.

The Alere Cholestech LDX® System for a Complete Lipid Profile

Tests performed

Lipid Profile Lipid Profile·GLU TC·HDL·GLU TC·HDL TC·GLU TC

Benefits at a glance

- CLIA-waived - no special training required
- Rapid results (just 5 minutes) - enables face-to-face counseling with patients
- Fingertick sampling - less painful and time consuming
- Reimbursed by Medicare and most private payers
- Small sample size (40µL) - easy to obtain
- Lab accurate results
- Improved office efficiencies - eliminates costly call backs to labs and patients

Alere Cholestech LDX® System: test per the guidelines¹ in office

- Screen adults every five years
- Test fasting lipid profile: total cholesterol (TC), HDL & LDL cholesterol, and triglycerides (TRG) for risk assessment and lipid management
- Titrate therapy and measure goal achievement for LDL, TRG, and non-HDL
- Test fasting glucose (GLU), HDL, TRG, blood pressure, and waist circumference to identify metabolic syndrome (any 3 or more)
- Demonstrated improvements related to adherence, therapeutic goal achievement, and measures of atherosclerotic burden⁶⁻⁹

Confidence in results

- Alere Cholestech LDX® System accuracy and reproducibility certified by the CDC's LSP and CRMLN programs* (the lipid testing accuracy standards)
- Used in thousands of physician offices, hospitals and employee wellness programs nationwide

Product ordering information

Cat. No.	Product	CPT Code †
10-959	Alere Cholestech LDX® System	-
10-991	Lipid Profile·GLU	80061 QW, 82947 QW
10-989	Lipid Profile	80061 QW
10-990	TC·HDL·GLU	82465 QW, 83718 QW, 82947 QW
10-987	TC·HDL	82465 QW, 83718 QW
10-988	TC·GLU	82465 QW, 82947 QW
10-986	TC	82465 QW
88769	Multianalyte Control Levels 1 and 2 (2 vials Level 1 & 2 vials Level 2, 2 mL each)	-
88773	Multianalyte Control Levels 1 and 2 (1 vial Level 1 & 1 vial Level 2, 0.25 mL each)	-

* The Lipid Standardization Program (LSP) certifies that laboratories are traceable to the CDC for total & HDL cholesterol and triglycerides; the Cholesterol Reference Method Laboratory Network (CRMLN) certifies manufacturers of clinical diagnostic products that measure total and HDL cholesterol.

† CPT codes provided are intended as general guidelines only. Alere and its distributors do not guarantee product coverage or reimbursement accuracy and appropriate usage of codes.

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
 2. Grundy SM et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-39.

3. Kuklina EV et al. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 2009; 302:2104-10.

4. Hyre AD et al. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007; 17:548-55.

5. Ghandehari H et al. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008; 156:112-9.

6. Haskell WL et al. Multifactor cardiovascular disease risk reduction in medically underserved, high-risk patients. Am J Cardiol 2006; 98:1472-9.

7. Howard BV et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008; 299:1678-89.

8. Bluml BM et al. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc (Wash) 2000; 40:157-65.

9. Tsuyuki RT et al. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med 2004; 116:130-3.



Call 1.877.441.7440 or visit alere.com today.